Menu
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€94.50

€94.50

1.610%
1.5
1.610%
-
 
18.08.26 / Frankfurt WKN: A2JGBF / Name: Medartis Holding / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Financial data and news for Medartis Holding

sharewise wants to provide you with the best news and tools for Medartis Holding, so we directly link to the best financial data sources.

News

The Medartis Group accelerates organic sales growth in H1 to 17.0% and achieves a core EBITDA margin of 18.0%
The Medartis Group accelerates organic sales growth in H1 to 17.0% and achieves a core EBITDA margin of 18.0%
The Medartis Group accelerates organic sales growth in H1 to 17.0% and achieves a core EBITDA margin of 18.0%
Invitation: Medartis half-year results presentation for 2026
Invitation: Medartis half-year results presentation for 2026
Invitation: Medartis half-year results presentation for 2026
Medartis wins the Swiss Medtech Award 2026
Medartis wins the Swiss Medtech Award 2026
Medartis wins the Swiss Medtech Award 2026
Medartis shareholders endorse Board proposals with strong support at AGM 2026
Medartis shareholders endorse Board proposals with strong support at AGM 2026
Medartis shareholders endorse Board proposals with strong support at AGM 2026
Medartis builds on momentum with 16% organic sales growth and core EBITDA margin exceeding 18%
Medartis builds on momentum with 16% organic sales growth and core EBITDA margin exceeding 18%
Medartis builds on momentum with 16% organic sales growth and core EBITDA margin exceeding 18%